Shui, L., Cheng, K., Li, X., Shui, P., Li, S., Peng, Y., . . . Cao, D. (2020). Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma. Front Immunol.
Chicago-stil citatShui, Lin, et al. "Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma." Front Immunol 2020.
MLA-referensShui, Lin, et al. "Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma." Front Immunol 2020.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.